Literature DB >> 23879542

Contributions of the histone arginine methyltransferase PRMT6 to the epigenetic function of RUNX1.

Joern Lausen1.   

Abstract

Hematopoietic differentiation is directed by transcription factors such as RUNX1. RUNX1 binds to specific DNA binding sites in regulatory elements of genes and recruits epigenetic cofactors to target loci. In this way histone modification patterns and the chromatin environment are altered, which results in adjusted gene expression. The process of transcription factor binding and cofactor recruitment is dynamic and strongly influenced by specific posttranslational modifications, which are triggered by signaling. In this way cellular signaling is integrated at the epigenetic level by transcription factors. The identification of epigenetic cofactors and the study of their epigenetic influence on transcription is crucial for the understanding of transcription factor function in differentiation and disease. In this article, the recent observation that RUNX1 is associated with the protein arginine methyltransferase 6 will be reviewed. PRMT6 triggers H3R2me2a at RUNX1 target genes; this histone modification negatively influences the positive H3K4me3 mark and this way acts repressive. The RUNX1/PRMT6 association has an impact on bivalent histone marks. Upon differentiation, a RUNX1 corepressor complex with PRMT6 is exchanged with a RUNX1 coactivator complex. Furthermore, the potential cross talk of transcription factors and epigenetic cofactors with histone marks will be discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23879542     DOI: 10.1615/critreveukaryotgeneexpr.2013007527

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  5 in total

1.  RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation.

Authors:  Olga N Kuvardina; Julia Herglotz; Stephan Kolodziej; Nicole Kohrs; Stefanie Herkt; Bartosch Wojcik; Thomas Oellerich; Jasmin Corso; Kira Behrens; Ashok Kumar; Helge Hussong; Henning Urlaub; Joachim Koch; Hubert Serve; Halvard Bonig; Carol Stocking; Michael A Rieger; Jörn Lausen
Journal:  Blood       Date:  2015-04-24       Impact factor: 22.113

2.  PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1.

Authors:  Lucas Schneider; Stefanie Herkt; Lei Wang; Christine Feld; Josephine Wesely; Olga N Kuvardina; Annekarin Meyer; Thomas Oellerich; Björn Häupl; Erhard Seifried; Halvard Bonig; Joern Lausen
Journal:  Oncogenesis       Date:  2021-05-17       Impact factor: 7.485

Review 3.  The Emerging Role of PRMT6 in Cancer.

Authors:  Zhixian Chen; Jianfeng Gan; Zhi Wei; Mo Zhang; Yan Du; Congjian Xu; Hongbo Zhao
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

4.  MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.

Authors:  Nicole Kohrs; Stephan Kolodziej; Olga N Kuvardina; Julia Herglotz; Jasmin Yillah; Stefanie Herkt; Alexander Piechatzek; Gabriela Salinas Riester; Thomas Lingner; Christian Wichmann; Halvard Bonig; Erhard Seifried; Uwe Platzbecker; Hind Medyouf; Manuel Grez; Jörn Lausen
Journal:  PLoS Genet       Date:  2016-03-18       Impact factor: 5.917

5.  Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34+ progenitor cells.

Authors:  Stefanie C Herkt; Olga N Kuvardina; Julia Herglotz; Lucas Schneider; Annekarin Meyer; Claudia Pommerenke; Gabriela Salinas-Riester; Erhard Seifried; Halvard Bonig; Jörn Lausen
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.